ClinicalTrials.gg
CompletedNCT04132570Updated Jan 22, 2021

A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution

A Phase 4 interventional study of Budesonide and Placebo in Rhinitis, sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Completed at 6 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division (formerly part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Rhinitis with a site in China — 7 open to participants now, 7 under way, 1 of them phase 3. Rhinitis · China.

Started
2019
with 1 other
Phase 4
3 of 12
1 open now
Registered
4th of 12
by date
Lead sponsor
1 of 12
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division

Among the 12 studies in Rhinitis with a site in China, this one is one of 2 that started in 2019, is one of 3 in phase 4, and was the 4th registered.

Rhinitis

246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.

Browse Rhinitis studies →

Open to participants now

7 of the 12 studies in Rhinitis with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 15 Rhinitis studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Rhinitis with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the effectiveness of intranasal budesonide aqueous spray 256 microgram (mcg)/day for treatment of rhinitis symptoms during times of high airborne pollution.

03

Conditions studied

  • Rhinitis

Browse trials for

Keywords

  • Airborne pollution
  • Rhinitis
  • Budesonide
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Self-reported rhinitis symptoms triggered or worsened by airborne pollution, with agreement by physician at screening visit
  • Participant must have moderate to severe rhinitis symptoms as defined by a 24-hour reflective total nasal symptom score (rTNSS) of at least 5 (maximum 9), based on three individual nasal symptom scores (nasal obstruction, secretion/runny nose, itching/sneezing) at the time of the screening visit, including at least one individual symptom score of 3 for nasal obstruction and/or secretion/runny nose
  • Regularly have outdoor exposure during a normal week in the winter season, including greater than or equal to (>=) 1 hour on most days. Outdoor exposure may include commuting activities (such as walking/bicycle/auto/bus/city metro train travel), outdoor work, exercise, shopping, or other outdoor activities
  • A woman of must have a negative urine pregnancy test (beta human chorionic gonadotropin [beta hCG]) at screening and agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 30 days after the last administration of study agent
  • Male participants who are not surgically sterilized and are heterosexually active with a woman of childbearing potential, must agree to use a barrier method of (example condom with spermicidal foam/gel/film/cream/suppository) and to not donate sperm during the study and for 30 days after last receiving study agent. Note that barrier methods must also be used in all male subjects sexually active with pregnant partners for at least 30 days after last study agent administration
  • Participants can understand the questionnaires and are able to complete the questionnaires in the format provided
  • Reside in the same city as the study site that they will be visiting

Exclusion criteria

Exclusion Criteria:

  • History of to budesonide or any ingredients in the formulation
  • Upper respiratory infection within 2 weeks of screening visit
  • Current symptoms consistent with diagnosis of common cold, influenza, or other respiratory infection according to physician evaluation
  • Using of N-95 masks days during with high airborne pollution
  • Presence of nasal polyps or deviated septum as confirmed by nasal endoscopy
  • History of nasal surgery
  • Presence of chronic or active rhinosinusitis or sinusitis
  • Systemic, intranasal or topical use within 1 month, intranasal or systemic decongestants within 3 days, antihistamine use within 1 week, intranasal cromolyn within 2 weeks, leukotriene use within 1 month, or immunotherapy within 2 years of screening visit
  • Asthma, with the exception of mild intermittent asthma not requiring medication
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (example compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    Budesonide 256 mcg per Day (Treatment A)

    Participants will self-administer 2 nasal sprays of Budesonide (64 microgram \[mcg\]/spray) in each nostril once daily (every morning) up to 10 +\\- 3 Days.

    Drug: Budesonide

  • Placebo comparator
    Placebo (Treatment B)

    Participants will self-administer 2 nasal sprays of matching placebo in each nostril once daily (in the morning) up to 10 +\\- 3 Days.

    Other: Placebo

Interventions

  • Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days.

    Also known as: RHINOCORT

  • OtherPlacebo

    Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days.

06

What researchers measure

Primary outcomes

  1. Mean Change from Baseline in 24-hour Reflective Total Nasal Symptom Score (rTNSS)

    Mean change from baseline in 24-hour reflective total nasal symptom score (rTNSS) calculated as the sum of the participant-assessed 24-hour reflective severity ratings for three individual nasal symptom scores (nasal obstruction, secretion/runny nose, itching/sneezing) averaged over the first 10-day treatment period. Baseline value will be a single 24-hour rTNSS recorded on the no-treatment evening following the baseline visit. The individual nasal symptom scores will be recorded at home by participants in their diary on a four point scale (from 0=none to 3=severe). The sum of the individual scores will form the 24-hour rTNSS.

    Time frame: Baseline up to 10 days (24 hours each day)

Secondary outcomes

  1. Subject Global Impression of Change (SGIC) at the Final Efficacy Assessment

    Participant will rate Global Impression of Change at Final Efficacy Assessment on a 5-point scale from 0 (symptoms were aggravated) to 4 (total control over symptoms). An increase in score indicates the improvement in condition.

    Time frame: Day 10 (+/-3)

  2. Mean Change from Baseline in Individual Nasal Symptoms Scores (NSS)

    Mean Change from Baseline in individual NSS for nasal obstruction, secretion/runny nose, and itching/sneezing averaged over the first 10-day treatment period will be reported using 4-point scale from 0=None, 1=Mild, 2=Moderate, or 3=Severe.

    Time frame: Baseline to 10 days (24 hours each day)

  3. Mean Change from Baseline in 24-hour Reflective Individual non-Nasal Symptoms Score (Cough and Post-Nasal Drip)

    Mean Change from Baseline in 24-hour reflective Individual non-Nasal Symptoms Score for cough and post-nasal drip averaged over the first 10-day treatment period, using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe condition.

    Time frame: Baseline to 10 days (24 hours each day)

  4. Number of Participants With Adverse Events (AEs) as a Measure of Safety

    An AE is any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

    Time frame: Up to Day 10 +/- 3 days or up to 30 days after the last day of the study treatment period (Day 10)

07

Study locations

6 sites
  • Beijing Tongren Hospital, Cmu
    Beijing, Beijing 100730, China
  • The No.2 Hospital of Baoding
    Baoding, Hebei 071051, China
  • Cangzhou Center Hospital
    Cangzhou, Hebei 061000, China
  • The Second Hospital to Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Shandong provincial hospital
    Jinan, Shandong 250117, China
  • The No.2 People'S Hospital Og Weifang
    Weifang, Shandong 261041, China
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Data sharing details ↗ · yoda.yale.edu

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Jan 2020, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2019
First posted
Oct 21, 2019
StartActual
Oct 22, 2019
Primary completionActual
Jan 22, 2020
CompletionActual
Jan 22, 2020
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04132570
Responsible party
Sponsor
First posted
Oct 21, 2019
Start date
Oct 22, 2019
Primary completion
Jan 22, 2020
Completion
Jan 22, 2020
Last update
Jan 22, 2021

Study contacts

Luo Zhang
principal investigator · BEIJING TONGREN HOSPITAL, CMU
Chunguang Shan
principal investigator · THE SECOND HOSPITAL TO HEBEI MEDICAL UNIVERSITY
Weiwei Liu
principal investigator · Cangzhou Center Hospital
Guoji Zhang
principal investigator · BAODING FIRST CENTER HOSPITAL
Yaozhong Han
principal investigator · The No. 2 Hospital of Baoding
Yongjian Ma
principal investigator · THE NO.2 PEOPLE'S HOSPITAL OG WEIFANG
Guanggang Shi
principal investigator · Shandong Provincial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion